OmniAb Inc. (OABI) is a Healthcare · Biotechnology company listed on NASDAQ. Price $4.47 (+0.68%), Market cap $0.29B, 52-week low–high $1.25 ~ $2.20.
OmniAb, Inc., a biotechnology company, licenses discovery research technology to pharmaceutical and biotech companies, and academic institutions to enable the discovery of therapeutics in the United States, Europe, Japan, China, and Canada. The company's technology platform creates and screens diverse antibody repertoires to identify optimal antibodies and other target-binding proteins for partners' drug development efforts. Its OmniAb platform's Biological Intelligence powers the immune systems of its proprietary and engineered transgenic animals to create optimized antibody candidates for human therapeutics. The company offers animal-based technologies include OmniRat, OmniChicken, and Omn
Financial statements, price targets, institutional (13F) holdings and related news for OmniAb Inc. are updated in real time on BlackAll Trade.
OmniAb Inc. trades at $4.47 (+0.68%). Real-time quotes and charts are available on BlackAll Trade.
OmniAb Inc. has a market cap of about $0.29B.
OmniAb, Inc., a biotechnology company, licenses discovery research technology to pharmaceutical and biotech companies, and academic institutions to enable the discovery of therapeutics in the United S